~~<i id='7B1F40ACCA'><strike id='7B1F40ACCA'><tt id='7B1F40ACCA'><pre id='7B1F40ACCA'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：comprehensive 2025-09-28 01:26:01 Page View：98

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Immunocompromised patients offer clues on chronic Covid
Next article： Heart attack and stroke risk calculators need revising

knowledge

Walensky prepares to leave CDC — and Congress — behind

OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

To bolster infectious disease surveillance, genomics powerhouses team up

TuliodeOliveiraleadsSouthAfrica’sCentreforEpidemicResponseandInnovation.CourtesyCERI@SULONDON—Twores

What does generative AI mean for health care? We asked experts

MikeReddyforSTATHealthcarecompaniesareracingtoincorporategenerativeAItoolsintotheirproductpipelinesa

Biotech investment managers search for lucrative opportunities

Fromleft,RodNathan,portfoliomanagerandpartnerofJ.Goldman&Co.;ARKInvestsenioranalystAliUrman;andP

WSS

explore

explore

Wikipedia

knowledge

Biotech investment managers search for lucrative opportunities